샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785735

세계의 아르테미시닌 병용요법 시장

Artemisinin Combination Therapy
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 194 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 아르테미시닌 병용요법 시장은 2030년까지 9억 4,010만 달러에 이를 전망

2024년에 6억 1,990만 달러로 추정되는 아르테미시닌 병용요법 세계 시장은 2030년에는 9억 4,010만 달러에 이르고, 분석 기간 2024-2030년 CAGR은 7.2%를 보일 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Artemether+Lumefantrin은 CAGR 8.2%를 나타내고, 분석 기간 종료시에는 3억 4,270만 달러에 이를 것으로 예측됩니다. Artesunate+Amodiaquine 부문의 성장률은 분석 기간중 CAGR 7.3%로 추정됩니다.

미국 시장은 1억 6,890만 달러로 추정, 중국은 CAGR11.4%로 성장 예측

미국의 아르테미시닌 병용요법 시장은 2024년에 1억 6,890만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2024-2030년의 분석 기간에 CAGR 11.4%로 성장을 지속하여, 2030년에는 1억 9,880만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 3.5%와 7.0%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.8%를 보일 전망입니다.

세계의 아르테미시닌 병용요법 시장 - 주요 동향과 촉진요인 정리

아르테미시닌 병용요법은 전 세계 건강 문제를 어떻게 해결하고 있는가?

아르테미시닌 병용요법(ACT)은 말라리아 치료의 표준으로 인정받고 있으며, 특히 아프리카와 동남아시아에서 공중보건에 큰 도전이 되고 있는 말라리아 치료의 황금 표준으로 인정받고 있습니다. 이 치료법은 아르테미시닌 유도체와 파트너 약물을 결합하여 효능을 높이고 내성을 감소시키는 치료법입니다. 세계보건기구(WHO)가 ACT를 1차 선택 약품으로 권고한 이후, ACT는 말라리아가 유행하는 지역 전체에서 널리 채택되고 있습니다. 정부 및 세계기금, 유니세프와 같은 비정부기구는 대규모 조달 및 보조금 지급 프로그램을 통해 ACT에 대한 접근성을 보장하는 데 매우 중요한 역할을 하고 있습니다. 최근의 기술 혁신에는 약제 내성 말라리아 균주의 출현에 대응하기 위해 고안된 3제 병용 요법 등이 포함되며, 시장이 적응성과 회복력에 중점을 두고 있음을 알 수 있습니다.

ACT의 가용성에서 기술의 역할은 무엇인가?

약물의 제형화 및 생산 기술의 발전으로 ACT의 접근성이 향상되고 있습니다. 나노입자 기반 전달 시스템, 분산성 정제 등의 기술 혁신으로 ACT는 특히 소아 및 사회적 약자에게 더욱 효과적이고 환자 친화적인 치료법이 되었습니다. 디지털 추적 시스템으로 뒷받침되는 공급망 최적화를 통해 ACTs를 원격지에 적시에 배송할 수 있도록 보장합니다. 또한, 모바일 헬스(m헬스) 플랫폼의 등장으로 ACT 요법에 대한 인식과 순응도가 향상되고 있습니다. 이러한 플랫폼을 통해 의료진은 지역사회를 교육하고, 치료 진행 상황을 추적하고, 질병 발생을 모니터링할 수 있어 시장의 성장과 효과 향상에 기여하고 있습니다.

세계 이니셔티브는 어떻게 시장 확대를 촉진하고 있는가?

국제적인 협력 관계와 자금 지원은 ACT 시장의 중요한 촉진요인입니다. Roll Back Malaria나 Medicines for Malaria Venture(MMV)와 같은 프로그램은 ACT의 접근성을 높이는 동시에 내성에 대응하기 위한 새로운 약물 조합에 대한 연구를 촉진하는 데 중점을 두고 있습니다. 복합제 도입으로 투약이 간소화되어 환자의 순응도가 향상되었습니다. 또한, 말라리아가 유행하는 지역의 정부는 말라리아 퇴치 캠페인에 많은 투자를 하고 있으며, 여기에는 대량 약물 투여 및 ACT 배포를 위한 보조금도 포함되어 있습니다. 이러한 노력을 보완하는 것이 비상장사이며, 제약사들은 생산 확대와 구매하기 쉬운 가격 확보에 주력하고 있습니다.

ACT 시장의 성장 원동력은 무엇인가?

아르테미시닌 병용요법 시장의 성장 원동력은 말라리아의 확산 증가와 말라리아 퇴치를 위한 전 세계 노력 등 여러 요인에 기인합니다. 인식 개선 활동 증가로 진단율과 치료율이 향상되면서 ACT에 대한 수요가 증가하고 있습니다. 의약품 제조의 발전으로 제조비용이 절감되어 저소득 지역에서도 ACTs를 쉽게 이용할 수 있게 되었습니다. 내성균 대책으로 병용요법이 채택되고, 민관 파트너십이 확대되면서 시장은 더욱 확대되고 있습니다. 또한, 백신 접종 프로그램 등 다른 헬스케어 이니셔티브와 ACT의 유통을 통합함으로써 치료 효과를 극대화하고 시장의 견고한 성장을 보장할 수 있습니다.

부문

유형(아르테메이텔＋르메판트린, 아르테스네이트＋아모지아킨, 지히드로아르테미시닌＋피페라킨, 아르테스네이트＋메후로킨, 아르테스네이트＋스르파드키신피리메타민, 피로나리진아르테스네이트, 기타 유형)

조사 대상 기업 예

  • Ajanta Pharma Ltd.
  • Bliss GVS Pharma Ltd.
  • DENK PHARMA GmbH & Co. KG
  • Hovid Berhad
  • Ipca Laboratories Ltd.
  • KPC Pharmaceuticals, Inc.
  • Macleods Pharmaceuticals Ltd.
  • Novartis AG
  • Sanofi S.A.
  • Shanghai Desano Bio-Pharmaceutical Co., Ltd.
  • Shanghai Fosun Pharmaceutical(Group) Co. Ltd.
  • Shin Poong Pharm Co. Ltd.
  • Sumaya Biotech GmbH & Co. KG

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴로 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH

Global Artemisinin Combination Therapy Market to Reach US$940.1 Million by 2030

The global market for Artemisinin Combination Therapy estimated at US$619.9 Million in the year 2024, is expected to reach US$940.1 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Artemether+Lumefantrine, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$342.7 Million by the end of the analysis period. Growth in the Artesunate+Amodiaquine segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.9 Million While China is Forecast to Grow at 11.4% CAGR

The Artemisinin Combination Therapy market in the U.S. is estimated at US$168.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$198.8 Million by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Artemisinin Combination Therapy Market - Key Trends & Drivers Summarized

How Is Artemisinin Combination Therapy Addressing Global Health Challenges?

Artemisinin Combination Therapy (ACT) is recognized as the gold standard for treating malaria, a disease that continues to pose significant public health challenges, particularly in Africa and Southeast Asia. This therapy combines artemisinin derivatives with partner drugs to enhance efficacy and reduce resistance. WHO's recommendation of ACT as the first-line treatment has driven its widespread adoption across malaria-endemic regions. Governments and non-governmental organizations, such as the Global Fund and UNICEF, are playing a pivotal role in ensuring access to ACTs through large-scale procurement and subsidized distribution programs. Recent innovations include triple-combination therapies designed to combat emerging drug-resistant malaria strains, underscoring the market’s focus on adaptability and resilience.

What Role Does Technology Play in ACT Accessibility?

Technological advancements in drug formulation and production are improving the accessibility of ACTs. Innovations such as nanoparticle-based delivery systems and dispersible tablets have made the therapy more effective and patient-friendly, particularly for children and vulnerable populations. Supply chain optimization, supported by digital tracking systems, ensures timely delivery of ACTs to remote areas. Furthermore, the rise of mobile health (mHealth) platforms is enhancing awareness and adherence to ACT regimens. These platforms allow healthcare workers to educate communities, track treatment progress, and monitor disease outbreaks, contributing to the market's growth and efficacy.

How Are Global Initiatives Driving Market Expansion?

International collaborations and funding initiatives are critical drivers of the ACT market. Programs like Roll Back Malaria and Medicines for Malaria Venture (MMV) focus on increasing the availability of ACTs while promoting research into new drug combinations to address resistance. The introduction of fixed-dose combinations has simplified administration, improving patient compliance. Additionally, governments in endemic regions are investing heavily in malaria eradication campaigns, which include mass drug administration and subsidies for ACT distribution. These efforts are complemented by private sector involvement, with pharmaceutical companies focusing on scaling up production and ensuring affordability.

What Drives the Growth of the ACT Market?

The growth in the Artemisinin Combination Therapy market is driven by several factors, including the increasing prevalence of malaria and global efforts to eradicate the disease. Rising awareness campaigns have led to improved diagnosis and treatment rates, fueling demand for ACTs. Advances in pharmaceutical manufacturing have reduced production costs, making these therapies more accessible in low-income regions. The adoption of combination therapies to combat resistance and the expansion of public-private partnerships are further enhancing market reach. Additionally, the integration of ACT distribution with other healthcare initiatives, such as vaccination programs, maximizes the therapy's impact, ensuring robust growth for the market.

SCOPE OF STUDY:

The report analyzes the Artemisinin Combination Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate, Other Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Ajanta Pharma Ltd.
  • Bliss GVS Pharma Ltd.
  • DENK PHARMA GmbH & Co. KG
  • Hovid Berhad
  • Ipca Laboratories Ltd.
  • KPC Pharmaceuticals, Inc.
  • Macleods Pharmaceuticals Ltd.
  • Novartis AG
  • Sanofi S.A.
  • Shanghai Desano Bio-Pharmaceutical Co., Ltd.
  • Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
  • Shin Poong Pharm Co. Ltd.
  • Sumaya Biotech GmbH & Co. KG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Artemisinin Combination Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Artemisinic Acid in Anti-Malarial Drug Production
    • Increasing Research on Synthetic Biology & Bioengineering of Artemisinic Acid
    • Surging Interest in Artemisinic Acid for Anti-Cancer & Immunotherapy Research
    • Expanding Use of Artemisinic Acid in Veterinary Medicine
    • Technological Advancements in Fermentation-Based Production of Artemisinic Acid
    • Rising Investments in Pharmaceutical R&D for Artemisinic Acid Applications
    • Increasing Demand for Cost-Effective & Scalable Artemisinic Acid Synthesis
    • Growing Role of Artemisinic Acid in Combating Emerging Infectious Diseases
    • Expanding Focus on Sustainable Artemisinic Acid Production from Plant Sources
    • Surging Demand for Artemisinic Acid in Herbal & Traditional Medicine
    • Increasing Government & NGO Support for Malaria Eradication Programs
    • Growing Availability of Artemisinic Acid Through Synthetic Pathway Innovations
    • Expanding Role of Artemisinic Acid in Personalized Medicine & Drug Formulations
    • Rising Collaborations Between Pharmaceutical Companies & Biotech Firms
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artemisinin Combination Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Artemisinin Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Artemether+Lumefantrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Artemether+Lumefantrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Artemether+Lumefantrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Artesunate+Amodiaquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Artesunate+Amodiaquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Artesunate+Amodiaquine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dihydroartemisinin+Piperaquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dihydroartemisinin+Piperaquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Dihydroartemisinin+Piperaquine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Artesunate+Mefloquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Artesunate+Mefloquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Artesunate+Mefloquine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Artesunate+Sulfadoxine-Pyrimethamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Artesunate+Sulfadoxine-Pyrimethamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Artesunate+Sulfadoxine-Pyrimethamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pyronaridine-Artesunate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pyronaridine-Artesunate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pyronaridine-Artesunate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • CHINA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Artemisinin Combination Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Europe 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: France 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 47: Germany Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Germany 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Italy 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 53: UK Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: UK 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 56: Spain Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Spain Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Spain 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 59: Russia Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Russia Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Russia 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Rest of Europe 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Artemisinin Combination Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Asia-Pacific 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Asia-Pacific 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 71: Australia Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Australia Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Australia 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • INDIA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: India 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 77: South Korea Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: South Korea Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: South Korea 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Asia-Pacific Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Rest of Asia-Pacific 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Artemisinin Combination Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Latin America 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Latin America Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Latin America 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 89: Argentina Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Argentina Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Argentina 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 92: Brazil Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Brazil Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Brazil 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 95: Mexico Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Mexico Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Mexico 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Latin America Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Latin America 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Artemisinin Combination Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Middle East 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 104: Middle East Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Middle East Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Middle East 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 107: Iran Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Iran Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Iran 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 110: Israel Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Israel Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Israel 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Saudi Arabia Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Saudi Arabia 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 116: UAE Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UAE Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UAE 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Middle East Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Middle East 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 122: Africa Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Africa Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Africa 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제